Brief: Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors

Faeth Therapeutics,

27/03/2025 20:55

March 27 (Reuters) - Sensei Biotherapeutics Inc SNSE.O:

SENSEI BIOTHERAPEUTICS REPORTS FAVORABLE PRELIMINARY DOSE EXPANSION DATA FOR SOLNERSTOTUG IN PD-(L)1 RESISTANT TUMORS

SENSEI BIOTHERAPEUTICS INC: EARLY DATA SUGGEST SOLNERSTOTUG MAY PROVIDE A MEANINGFUL CLINICAL BENEFIT IN SELECT TUMOR TYPES

Source text: ID:nGNX5rXVZx

Further company coverage: SNSE.O

 ((Reuters.Briefs@thomsonreuters.com;))